Back to Top

"One of today's leaders in investor relations and shareholder services"

Category Archives: Articles

Progressive Care Inc.’s 2017 Moves Create a Solid Foundation for 2018 Growth in the Ever-changing Healthcare Space

Progressive Care Inc.’s 2017 Moves Create a Solid Foundation for 2018 Growth in the Ever-changing Healthcare Space

Progressive Care Inc.’s 2017 Moves Create a Solid Foundation for 2018 Growth in the Ever-changing Healthcare Space

The healthcare market moves at such a fast pace it can make anyone’s head spin. With a new federal administration and recent acquisitions by bigwigs like CVS, it’s time to start shedding more light on companies who are making their mark in a competitive space amidst all this constant change. Progressive Care Inc., headed by CEO S. Parikh Mars, managed to achieve $1.7 million in net revenue in November alone from the thousands of prescriptions filled during the month. Their year-over-year growth has been consistently positive, with revenue being up 10% in 2017 alone. Mars attributes their success and growth based on their many initiatives taken over the past year, and she’s optimistic about their future for some very good reasons.

Attention to Detail

Specializing in general prescriptions, medications, and administration support, Progressive Care Inc. is positioning itself to be a total solution for healthcare professionals in Florida and …

Continue Reading

Posted in Articles| Tagged , |

Oncolix, Inc. (ONCX) Continues to Impress by Reaching Important Milestones

The strength of a company isn’t found in the words they use to describe themselves, but in the everyday actions and accomplishments the company makes as it pushes forward. Oncolix (ONCX) is a biotechnology company developing a therapeutic protein that has managed to catch some major attention from regulators and investors alike. Its preliminary tests have already shown the signs of success to treat cervical, breast, ovarian, and uterine cancers. While the company has recently undergone some restructuring, their mission forward is clearer than ever before.

A Fresh Start

The company recently changed its stock symbol, began trading, and announced its intent to hit NASDAQ with a splash. CEO Michael Redman has gone to great lengths to bring unity to the company, so everyone is on the same page as the company prepares for its next steps. By shifting focus to their most promising development, Prolanta™, they hope to …

Continue Reading

Posted in Articles| Tagged , |

New Technology, New Vision, New Focus: What Sets Vemanti Apart

Vemanti (Pink Sheets: VMNT) is a public company that was founded on looking toward the future of technology, which is why we’ve set our sights on investments in the blockchain technology space. With a number of projects already underway, it’s an exciting time to be getting in on the ground floor of this game-changing innovation. Learn more about how we’re shaking up the status quo and what makes us different from our competitors.

Why the Blockchain?

The blockchain technology is the driving force behind famous cryptocurrencies such as Bitcoin and Ethereum. This distributed ledger keeps a record of every transaction and it’s practically eliminated the chances of fraud or human error. While digital currency may spark a controversial response depending on who’s doing the talking, the blockchain has been universally praised by everyone from government officials to CEOs of big banks. Vemanti saw the potential of the blockchain long …

Continue Reading

Posted in Articles| Tagged , |

VMNT Business Focus and Advantages Set Them Apart from the Competition

Block Chain

Vemanti Group Inc., a Nevada corporation with headquarters in Newport Beach, CA. Post-revenue and cash-flow positive, the Company is technology-driven with a pure focus on blockchain-based innovations. It drives growth through investment and acquisition of early-stage companies with potential for explosive growth in the US and global markets. Its investment targets are startups with blockchain‐based products and services, especially FinTech and E‐Commerce solutions. The Company is also capable of developing new subsidiaries of its own.

About Vemanti Group Founded in 2014, the Company is publicly traded on OTC Markets (OTC: VMNT). Its goal is to be a multi-asset technology holding and investment company focused on the emerging markets of blockchain-linked products and services with projected strong growth in the next few decades. Vemanti makes it easier for entrepreneurs to be part of a public company and for smaller investors to penetrate opportunities in emerging technologies without going through Private Equity …

Continue Reading

Posted in Articles| Tagged |
HempMeds® Brazil

HempMeds Brazil Scores Key Legal Victory and Gains Notoriety

HempMeds® Brazil

Medical Marijuana Inc. (OTC MJNA) has received recognition over the past year for its innovative products and successful marketing, which have made it a forerunner in the field of medicinal marijuana. The company and its subsidiary, Kannaway, accomplished record sales over the course of the past year. Now, another of Medical Marijuana Inc.’s subsidiaries, HempMeds®, is proving itself as a revolutionary as well, reforming the traditional views on marijuana in Brazil.

Who is HempMeds® Brazil?

HempMeds® is a subsidiary of Medical Marijuana Inc., which is a company that focuses on cannabis and hemp products. HempMeds® Brazil is the first company to gain legal approval to ship cannabis-related products into Brazil. All three products currently manufactured by HempMeds® Brazil are subsidized under Brazil’s health care system through the government. Their products are designed to treat conditions like epilepsy and Parkinson’s as well as chronic pain. As of now, the company …

Continue Reading

Posted in Articles| Tagged , , , , |

Oncolix, Inc. Corporate’s Moves Highlight a Company Making the Right Moves at the Right Time

In today’s world, when a company takes the next step is just as important as the strides the company takes. This is especially the case when it comes to the pharmaceutical industry. Drugs in high demand appearing at exactly the right time have the ability to benefit the business as well as patients. Changes in the infrastructure of a business at exactly the right time have the ability to promote growth, which ultimately benefits the patients. Oncolix, Inc. is proving this is the case.

Who is Oncolix, Inc.

Oncolix, Inc. (OTC: AEPP) is a biotechnology company developing the drug, Prolanta™. This particular medication is a treatment for uterine, breast, ovarian and other cancers. As of now, the company has gained U.S. FDA clearance to proceed with human testing for the drug for the treatment of ovarian cancer. The Phase I clinical trial of Prolanta™ began in 2016 as a …

Continue Reading

Posted in Articles| Tagged , |